Alyacoubi S

Breininger SP

Lang CCJ

Lloyd M

Pickering O

Rahman S

Underwood T

English

\ua9 2022 by the authors. Licensee MDPI, Basel, Switzerland.Oesophageal cancer (OC) is the ninth most common cancer worldwide. Patients receive neoadjuvant therapy (NAT) as standard of care, but less than 20% of patients with oesophageal adenocarcinoma (OAC) or a third of oesophageal squamous cell carcinoma (OSCC) patients, obtain a clinically meaningful response. Developing a method of determining a patient’s response to NAT before treatment will allow rational treatment decisions to be made, thus improving patient outcome and quality of life. (1) Background: To determine the use and accuracy of microRNAs as biomarkers of response to NAT in patients with OAC or OSCC. (2) Methods: MEDLINE, EMBASE, Web of Science and the Cochrane library were searched to identify studies investigating microRNAs in treatment na\uefve biopsies to predict response to NAT in OC patients. (3) Results: A panel of 20 microRNAs were identified as predictors of good or poor response to NAT, from 15 studies. Specifically, miR-99b, miR-451 and miR-505 showed the strongest ability to predict response in OAC patients along with miR-193b in OSCC patients. (4) Conclusions: MicroRNAs are valuable biomarkers of response to NAT in OC. Research is needed to understand the effects different types of chemotherapy and chemoradiotherapy have on the predictive value of microRNAs; studies also require greater standardization in how response is defined

Newcastle University E-Prints

The Use of miRNAs in Predicting Response to Neoadjuvant Therapy in Oesophageal Cancer

https://eprints.ncl.ac.uk/file_store/production/294531/1F43DB79-368D-435B-A6B6-B2F680E835E2.pdf

The Use of miRNAs in Predicting Response to Neoadjuvant Therapy in Oesophageal Cancer

Abstract

Similar works

Full text

Available Versions

Newcastle University E-Prints